Global T-Cell Immunotherapy Pipeline Analysis 2016-2017: Pipeline is Very Strong with a Total of 139 Drug … – Yahoo Finance
|
Global T-Cell Immunotherapy Pipeline Analysis 2016-2017: Pipeline is Very Strong with a Total of 139 Drug …
Yahoo Finance The T-cell immunotherapy pipeline is very strong with a total of 139 drug candidates. Pharma giant such as Novartis, Kite Pharmaceuticals, Juno Therapeutics, Inc. and Sorrent Therapeutics, Inc. are actively involved in development of these therapeutics. |
